Multiple Myeloma Hub

The Multiple Myeloma Hub spoke with Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University, Paris, FR. We asked, What is the impact of elranatamab on quality of life (QoL) in relapsed/refractory multiple myeloma (RRMM)? Mohty discussed the impact of elranatamab on QoL in patients with RRMM, highlighting its benefits in symptom relief, mobility, and overall well-being. Mohty also addressed the associated risk of cytokine release syndrome (CRS), neurotoxicity, and infections, concluding with the latest clinical trial data and emphasizing the need for ongoing research to optimize the role of elranatamab and other bispecific antibodies in patient care.  Key learningsOverall, elranatamab has positively impacted QoL in many patients with RRMM by providing rapid symptom relief, reducing bone pain and fatigue, improving mobility, and decreasing healthcare visits. Better disease control also contributes to improved psychological well-being. These benefits ultimately enhance daily functioning and overall well-being, allowing patients to resume their daily activities. Adverse events are a concern; however, the implementation of step-up dosing helps to reduce the risks of severe CRS and neurotoxicities. The risk of infections remains significant. However, mitigation strategies such as prophylactic antivirals, antifungals, and intravenous immunoglobulin administration can help preserve QoL. Clinical trial data from the MagnetisMM-3 (NCT04649359) trial support these findings, demonstrating improved patient-reported outcomes in global health status, functional ability, and symptom management. Ongoing trials aim to further clarify the role of elranatamab and other bispecific antibodies in enhancing QoL. This educational resource is independently supported by Pfizer. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.  Hosted on Acast. See acast.com/privacy for more information.

During the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint satellite symposium entitled ‘Sequencing immune-based therapies in B-cell malignancies’. Here the Multiple Myeloma Hub is pleased to share the session: Next wave of immune-based therapies: What you need to know, which focused on relapsed/refractory (R/R) multiple myeloma (MM) and was presented by Krina Patel, MD Anderson Cancer Center, Houston, US. This activity was supported through an educational grant from Bristol Myers Squibb. Hosted on Acast. See acast.com/privacy for more information.

Ciltacabtagene autoleucel (cilta-cel) is a B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T-cell therapy, which is one of only two U.S. Food and Drug Administration (FDA)-approved CAR T-cell therapies for the treatment of relapsed/refractory multiple myeloma (RRMM). Both approved CAR T-cell agents are indicated in the heavily pre-treated setting after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.However, in February 2024, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of cilta-cel after at least one prior line of therapy, including an immunomodulatory agent or proteasome inhibitor, for those who have progressed on the last therapy and are refractory to lenalidomide.The Multiple Myeloma Hub is pleased to summarize the rationale for and latest data from clinical trials of cilta-cel after one to three lines of therapy for the treatment of MM.Read the article here: https://multiplemyelomahub.com/medical-information/integrating-cilta-cel-into-earlier-lines-of-therapy-rationale-and-latest-data-from-cartitude-2-and-cartitude-4 Hosted on Acast. See acast.com/privacy for more information.

During the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint satellite symposium entitled ‘Sequencing immune-based therapies in B-cell malignancies’. Here, the Multiple Myeloma Hub is pleased to share the session, which covered how to sequence CAR T-cell therapy and bispecific antibodies in relapsed/refractory (R/R) multiple myeloma (MM), presented by Sagar Lonial, Winship Cancer Institute of Emory University, Atlanta, US. Hosted on Acast. See acast.com/privacy for more information.

During the 65th American Society of Hematology Annual Meeting and Exposition, Dima presented results from a retrospective analysis to evaluate the real-world safety and efficacy of teclistamab, with a focus on patients who would have been ineligible for the MajesTEC-1 trial. We summarize the key findings in this podcast.To read this article on the Multiple Myeloma Hub, click here: https://multiplemyelomahub.com/medical-information/teclistamab-real-world-safety-and-efficacyThis educational resource is independently supported by Johnson & Johnson. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource. Hosted on Acast. See acast.com/privacy for more information.

During the Multiple Myeloma Hub Steering Committee Meeting in May 2024, key opinion leaders met to discuss key considerations regarding infections associated with bispecific antibodies. Meral Beksaç​ opened with a presentation reviewing the infectious complications associated with bispecific antibodies, and current treatment algorithms for such infections. Beksaç​ explored an analysis of infections and parameters of humoral immunity in the MonumenTAL-1 study, the clinical management of infections, and regional differences in access to prophylaxis and treatment for infections. Following her presentation, Beksaç​ chaired a Q&A session featuring Hermann Einsele, Paul Richardson, Heinz Ludwig, María-Victoria Mateos, Elena Zamagni, and Vania Tietsche De Moraes Hungria. Discussions included COVID infections, the need for vaccination in donors of immunoglobulins for IVIG treatment, and the impact of dosing schedules on reducing infectious complications and T‑cell exhaustion.  Hosted on Acast. See acast.com/privacy for more information.

During the Multiple Myeloma Hub Steering Committee Meeting in May 2024, key opinion leaders met to discuss the current use of CAR T-cell therapies in clinical practice, with a focus on patient-specific considerations in the development of personalized treatment plans. To open, Hermann Einsele provides a presentation reviewing the latest data from trials of ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel) in relapsed/refractory multiple myeloma (RRMM), including the KarMMa and CARTITUDE trials. He explores criteria for the identification of patients who may benefit from CAR T-cell therapy, mechanisms of resistance to BCMA CAR T-cell therapy, and the rationale for the earlier application of CAR T-cell therapies in MM. Einsele provides a review of the toxicities associated with immunotherapies, including strategies for prevention and monitoring, management techniques for CRS and ICANS, and infection prophylaxis and management. Following his presentation, Einsele chaired a Q&A session featuring Paul Richardson, Heinz Ludwig, María-Victoria Mateos, Meral Beksaç, Elena Zamagni, and Vania Tietsche De Moraes Hungria. Discussions included the implementation of CAR T-cell therapies in earlier lines of therapy, CAR T-cell therapies in high-risk disease, maintenance after CAR T-cell therapies, and toxicities with CAR T-cell therapies and bispecifics. This educational resource is independently supported by Bristol Myers Squibb. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.  Hosted on Acast. See acast.com/privacy for more information.

Experts Shaji Kumar and Naresh Bumma discuss selecting maintenance therapies post-ASCT for high-risk MM. They debate lenalidomide monotherapy vs. combination therapy with a proteosome inhibitor, the challenges of defining high-risk populations, and the need for prospective trials. Kumar and Bumma share their management strategies and highlight the future of managing high-risk MM post-ASCT.

The Multiple Myeloma Hub was pleased to speak to Hira Mian, McMaster University, Hamilton, CA. We asked, Should risk-adapted MM treatment be informed by age or frailty status?In this podcast, Hira Mian discusses the relationship between age and frailty status, sharing her perspective on how they may inform treatment strategies for patients with multiple myeloma. Mian examines the influence of age on frailty status, but notes other influential factors featured in the International Myeloma Working Group (IMWG) frailty score. Mian concludes with the importance of a comprehensive frailty assessment to inform a risk-adapted treatment plan. Hosted on Acast. See acast.com/privacy for more information.

Discover how immune reconstitution is studied in patients who stop therapy after achieving MRD negativity. Hear about markers for humoral immune recovery, infection rates, and potential implications for future studies.